Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096143 · ClinicalTrials.gov registry record
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 42,269
- Enrollment target
NCT05096143 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 42,269 participants.
The verdict
NCT05096143 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 42,269 participants
- Enrollment target
Study Summary
A non-interventional retrospective cohort study conducted to compare the naive sacubitril/valsartan Heart Failure with reduced Ejection Fraction (HFrEF) patient population to a matched naive ACEi/ARB HFrEF patient population.
Interventions
- DRUG Sacubitril/valsartan
- DRUG ACEi/ARB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,269 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2020-10-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05096143
The ClinicalTrials.gov registry entry for NCT05096143 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42,269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sacubitril/valsartan is the first listed.
NCT05096143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05096143 about?
NCT05096143 is a clinical study titled "A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data". A non-interventional retrospective cohort study conducted to compare the naive sacubitril/valsartan Heart Failure with reduced Ejection Fraction (HFrEF) patient population to a matched naive ACEi/ARB HFrEF patient population.
What is the current status of trial NCT05096143?
This trial is currently completed. The enrollment target is 42,269 participants. The study started on 2020-06-03. Estimated completion is 2020-10-19.
What interventions are being tested in trial NCT05096143?
The interventions under investigation include: Sacubitril/valsartan (DRUG), ACEi/ARB (DRUG).
Who is sponsoring clinical trial NCT05096143?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.